Buy SILDIGRA-100 Online

$4.13

CHARACTERISTICS
ACTIVE HALF-LIFE 4-5 HOURS
CLASSIFICATION PDE5 INHIBITOR
DOSAGE MEN 100 MG/DAY
ACNE NO
WATER RETENTION NO
HBR POSSIBLE
HEPATOTOXICITY NO
AROMATIZATION NO
ACTIVE SUBSTANCE SILDENAFIL
FORM 10 PILLS X 100 MG
MANUFACTURER RSM PHARMA

-
+
Compare

Description

Sildigra-100 is a medication used to treat erectile dysfunction (ED) in men. The active substance in Sildigra-100 is sildenafil, which is a phosphodiesterase type 5 (PDE5) inhibitor. The medication has an active half-life of 4-5 hours after being taken orally. It is classified as a PDE5 inhibitor and is available in a 100mg daily dose for men.

Unlike some other medications used to treat ED, Sildigra-100 is unlikely to cause acne or water retention side effects. However, it is possible to experience headaches, nausea, dizziness, or heartburn after taking this medication. Additionally, there is a possibility of high blood pressure associated with taking Sildigra-100.

One of the advantages of taking Sildigra-100 is that it is not hepatotoxic and does not cause aromatization. The medication is available in blister packs of 10 pills, with each pill containing 100mg of sildenafil. The manufacturer of Sildigra-100 is RSM Pharma, a reputable pharmaceutical company.

In conclusion, Sildigra-100 is a medication used to treat erectile dysfunction in men. Its active substance is sildenafil, which is a PDE5 inhibitor. The medication has a short active half-life of 4-5 hours and is available in a daily dose of 100mg. However, it is important to consult with a healthcare provider before taking Sildigra-100 as it can have side effects and interact with other medications.

Chemical name: 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
Formula: C28H38N6O11S
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid

 

Reviews

There are no reviews yet.

Be the first to review “Buy SILDIGRA-100 Online”

Your email address will not be published. Required fields are marked *